Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
 Annual Meeting - EconoTimes)
EAGAN, Minn., May 31, 2017 -- Biothera Pharmaceuticals, Inc. announced today that a poster about the design of IMPRIME-1™, the company’s ongoing Phase 2 clinical trial in advanced melanoma/triple negative breast cancer, will be presented at the 2017 ASCO Annual Meeting, taking place in Chicago, IL, June 2-6, 2017. The ASCO presentation details are as follows:
| Session Date & Time: | Monday, June 5, 2017, 8:00 AM – 11:30 AM Central Time |
| Session: | Developmental Therapeutics—Immunotherapy |
| Presentation Title: | A multicenter, open-label, phase II study of PGG beta-glucan and pembrolizumab in patients (pts) with advanced melanoma (MEL) following progression on treatment with checkpoint inhibitors (CPI) or triple negative breast cancer (TNBC) failing front-line chemotherapy for metastatic disease. |
| Session Location: | McCormick Place, Hall A, Poster Board #193a |
| Abstract No.: | TPS3105 |
Biothera announced earlier this year initiation of patient dosing in the Phase 2 study, which is evaluating the Company’s Imprime PGG in combination with KEYTRUDA® (pembrolizumab), the anti-PD-1 therapy marketed by Merck (known as MSD outside the United States and Canada). The multi-center, open-label study is anticipated to enroll up to 71 patients who have tested positive for a biomarker that may identify patients with higher probability of responding to Imprime PGG combination therapy. Additional information on the trial is available by visiting clinicaltrials.gov.
About Biothera Pharmaceuticals, Inc.
Biothera Pharmaceuticals is a privately held biotechnology company developing Imprime PGG, a Phase 2 cancer immunotherapy that enhances the efficacy of anti-cancer immune response in combination with immune checkpoint inhibitor, tumor-targeting and anti-angiogenesis antibodies. Biothera Pharmaceuticals has clinical research agreements with Merck to evaluate Imprime PGG and KEYTRUDA in Phase 2 studies in advanced melanoma, metastatic triple negative breast cancer, and head and neck squamous cell cancer. This therapeutic combination also is the focus of a Big Ten Cancer Research Consortium Phase 1b/2 trial in patients with non-small cell lung cancer. Imprime PGG has demonstrated a favorable safety profile in more than 400 subjects and signals of activity in multiple combinations and tumor types.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Contact: David Walsh Communications Biothera Pharmaceuticals, Inc. 651-256-4606 [email protected]
